Last reviewed · How we verify

NCT04575701

Long-term Outcome of TNF Alpha Therapy in IBD

Completed Last updated 25 February 2021
What this trial tests

trial testing TNF Alpha therapy in IBD in 538 participants. Completed in 1 July 2020.

Timeline
1 May 2019
Primary endpoint
1 June 2020
1 July 2020

Quick facts

Lead sponsorMedical University of Graz
StatusCompleted
Study typeOBSERVATIONAL
Enrollment538
Start date1 May 2019
Primary completion1 June 2020
Estimated completion1 July 2020
Sites1 location across Austria

Drugs / interventions tested

Conditions studied

Sponsor

Medical University of Graz

Who can join

Eligibility, any sex, with IBD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this retrospective study is to assess the outcome of patients with inflammatory bowel disease (IBD) under TNF-alpha antibody therapy over a period of 20 years

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study.
    Blesl A, Binder L, Högenauer C, Wenzl H, et al · · 2021 · cited 23× · PMID 34151449 · DOI 10.1111/apt.16478

Verify or expand the search:

Other recruiting trials for IBD

Currently open trials in the same condition.

Other Medical University of Graz trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04575701.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing